In:
Future Oncology, Future Medicine Ltd, Vol. 18, No. 21 ( 2022-07), p. 2695-2707
Kurzfassung:
Plain language summary Patients with early-stage non-small-cell lung cancer have about a one in five chance of cancer recurrence, even after complete resection. Using agents targeting EGFR, known as adjuvant EGFR tyrosine kinase inhibitors, after surgery is an effective way for patients with EGFR-mutated non-small-cell lung cancer to prevent recurrence. However, the optimal agent with favorable efficacy and safety is yet to be determined. This study showed that adjuvant chemotherapy followed with osimertinib had the best efficacy, while adjuvant icotinib monotherapy had the best safety.
Materialart:
Online-Ressource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2021-1614
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2022
Permalink